• to lessen the potential risk of really serious cardiovascular (heart and blood vessel) difficulties in adults with type 2 diabetes and cardiovascular diseaseIn Oct 2024, Novo Nordisk posted a study on scientific journal Mother nature a couple of novel glucose-sensitive insulin NNC2215 that may reduce the potential risk of hypoglycemia in animal